used it successfully for assembling the first genome assembly of Atlantic cod [2] . I am such a fan of the program that I even wrote a user-focused manual for it (available at https://contig.wordpress.com).
I feel the fact that Newbler is not open source has hampered its use among scientists. Although I have no direct evidence for this statement, it is a fact that a number of studies that have compared programs for the assembly of sequencing data, such as GAGE (http://gage.cbcb.umd. edu/assemblers/index.html) and GAGE-B My interaction with Roche was very positive and, in a way, their response was reassuring: Newbler will not disappear. Unfortunately, we did not achieve what the signees and I hoped for: Newbler will remain closed source. This was of course a disappointment. In all fairness, however, Roche's position is understandable. They have invested, and continue to invest, in this software, which gives their platform a competitive advantage. Releasing the code will give at least one of their competitors (IonTorrent/Thermo Fisher Scientific) an advantage as it sells instruments -the Ion Torrent PGM and Proton -that produce a similar type of data.
It is interesting to note that Newbler is positioned in the middle between commercial, closed-access and opensource software. There is no fee for using it, which makes it very accessible and provides it with a clear advantage over commercial software. Nevertheless, Newbler suffers from many of the disadvantages of closed-source software: these are black boxes, with little to no insight available into the algorithms behind them or their inner workings. There are no peer-reviewed papers describing them. Old versions are often not available, hampering reproducibility. If the company decides to pull the software off the market, or to remove a feature that is important for some researchers' work, there is nothing that can be done. The closed-source, no-fee model has another potential problem, as there may not be an incentive for the company to provide support for the software. Luckily, this seems not to be the case for Newbler; Roche says that they record all bug reports and feature requests, and take these very seriously during development of the next version. There is, however, no transparency: their bug and feature trackers are as closed as the source code.
Interestingly, other companies who sell sequencing instruments have made important parts of the software they produce open source. Worth mentioning are Pacific Biosciences' SMRT Analysis package (www.pacbiodevnet.com and https://github.com/PacificBiosciences), Thermo Scientific's Ion Torrent mapping and variant calling software (https:// github.com/iontorrent) and Illumina's ISAAC aligner (https://github.com/sequencing). These companies clearly believe in the benefits of open-source software as part of their business model.
There will always be a market for commercial software, because of its ease of use and sometimes because it is just plainly better. I am a strong believer in openaccess software, and I believe this model has a bright future. Good, closed-source but free programs such as Newbler, which are in the middle of these two extremes, will surely have a user base. But Roche have missed a huge opportunity by not making Newbler a true opensource software. Not charging for closed-access software does not necessarily make it better than commercial software.
By the way, the petition to convince Roche to make Newbler open source is still open, feel free to add your signature! (https://docs.google.com/spreadsheet/viewform? formkey=dHRvZDFUcldvZXVnWmhvSnlMWDBLQ1E6MA).
